New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 24, 2014
08:51 EDTIDRAIdera candidate IMO-8400 likely to be failed drug, says Summer Street
Summer Street predicts Idera Pharmaceuticals' IMO-8400, a small-molecule toll-like receptor antagonist being tested as a treatment for psoriasis, will be a failed drug candidate. The firm says Idera is developing a third-generation product, IMO-9200, which indicates the company has low expectations for IMO-8400.
News For IDRA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 23, 2015
09:27 EDTIDRAIdera Pharmaceuticals Chief Medical Officer resigns
Idera Pharmaceuticals disclosed in a regulatory filing that Louis Brenner, M.D. resigned his positions as senior VP and Chief Medical Officer of Idera to accept a new role as the Chief Operating Officer of a privately-held biotechnology company. This change will become effective April 3.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use